Revolution Medicines, Inc., a Redwood City, CA-based newly formed developer of new therapies derived from natural products, raised $45m Series A financing.
Third Rock Ventures, LLC, participated in the foundation and the funding of the company.
Led by industry veteran founding president and chief executive officer Mark A. Goldsmith, M.D., Ph.D., also a partner at Third Rock Ventures, Revolution Medicines builds upon the vision of the company’s founder and scientific advisory board chairman, Martin D. Burke, M.D., Ph.D., professor of chemistry, University of Illinois at Urbana-Champaign, and Early Career Scientist of the Howard Hughes Medical Institute, who invented a method for synthesizing original compounds that are pharmaceutically optimized analogues of complex natural products.
The company has entered into an exclusive license agreement with the University of Illinois to practice and expand this technology, and is pursuing a rapid clinical development path with its lead antifungal program that originated in Dr. Burke’s laboratory.
Its first drug candidates aim to kill fungi while minimizing toxic effects on human cells.
In addition to Dr. Goldsmith and Dr. Burke, the team includes:
– David Pompliano, Ph.D., founding chief scientific officer,
– Peg Horn, J.D., general counsel and senior vice president, corporate development,
– Neil Exter, interim chief business officer, a member of Revolution Medicine’s board of directors and partner at Third Rock Ventures, and
– Alexis Borisy, a member of Revolution Medicines board of directors, a partner at Third Rock Ventures, and entrepreneur and chemical biologist.